Keywords: |
adult; clinical article; treatment outcome; treatment response; aged; overall survival; disease course; cancer recurrence; salvage therapy; cancer growth; disease classification; cancer radiotherapy; cancer staging; follow up; antineoplastic agent; letter; progression free survival; computer assisted tomography; neoplasm recurrence, local; antineoplastic combined chemotherapy protocols; hematopoietic stem cell transplantation; pathology; retrospective study; risk factor; karnofsky performance status; death; tumor recurrence; lactate dehydrogenase; lymphoma, large b-cell, diffuse; drug therapy; transplantation, autologous; autologous hematopoietic stem cell transplantation; autotransplantation; diffuse large b cell lymphoma; maximum standardized uptake value; cancer prognosis; planning target volume; palliative chemotherapy; humans; human; male; female; cyclophosphamide plus doxorubicin plus etoposide plus prednisolone plus rituximab plus vincristine; cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine
|